Dystrophic epidermolysis bullosa (DEB) is due to mutations in the type VII collagen (C7) gene. Potential therapies for DEB include (i) ex vivo gene therapy and (ii) intradermal injection of gene-corrected DEB fibroblasts, lentiviral vectors expressing C7 or recombinant C7 itself. With regard to molecular engineering, the dermal fibroblast has advantages over epidermal keratinocytes for delivering C7 to DEB patients. Dermatology (2006Dermatology ( ) 126, 708-710. doi:10.1038 The study in this issue by Goto and colleagues (2006) at the Hokkaido University Graduate School of Medicine makes a case that the target for gene therapy for dystrophic epidermolysis bullosa (DEB) should be the dermal fibroblast rather than the keratinocyte. These investigators provide evidence that when gene-corrected DEB skin cells are conformed into a skin equivalent and transplanted onto the backs of rodents, the type VII (anchoring fibril) collagen derived from dermal fibroblasts contributes more type VII to the basement membrane zone (BMZ) at the dermal-epidermal junction than do the genecorrected keratinocytes. This finding in vivo is interesting because in vitro it appeared that the gene-corrected DEB keratinocytes and fibroblasts they used expressed nearly equivalent amounts of type VII collagen. We and others have shown in vitro that both human keratinocytes and fibroblasts synthesize and excrete type VII collagen (Stanley et al., 1985; Woodley et al., 1985; Ryynanen et al., 1992) , but it was thought that in human beings in vivo most of the type VII collagen at the BMZ of the skin came from keratinocytes (Regauer et al., 1990) . Goto and co-workers (2006) bring us good news, however, because dermal fibroblasts are much easier to work with and propagate than human keratinocytes. The conditions for culturing human dermal fibroblasts are far less fastidious than those for culturing human keratinocytes, so technical considerations are lessened. Fibroblasts are more robust cells than keratinocytes and are much less susceptible to growth arrest and differentiation than epidermal sheets, which are fragile and must be used immediately (Hengge and Bardenheuer, 2004) . Furthermore, fibroblasts can be passaged 20-30 times in vitro, are easy to grow in larger numbers, and can be readily cloned: a single genetically modified fibroblast can be expanded to greater than 10 20 cells (Krueger, 2000) .
The study in this issue by Goto and colleagues (2006) at the Hokkaido University Graduate School of Medicine makes a case that the target for gene therapy for dystrophic epidermolysis bullosa (DEB) should be the dermal fibroblast rather than the keratinocyte. These investigators provide evidence that when gene-corrected DEB skin cells are conformed into a skin equivalent and transplanted onto the backs of rodents, the type VII (anchoring fibril) collagen derived from dermal fibroblasts contributes more type VII to the basement membrane zone (BMZ) at the dermal-epidermal junction than do the genecorrected keratinocytes. This finding in vivo is interesting because in vitro it appeared that the gene-corrected DEB keratinocytes and fibroblasts they used expressed nearly equivalent amounts of type VII collagen. We and others have shown in vitro that both human keratinocytes and fibroblasts synthesize and excrete type VII collagen (Stanley et al., 1985; Woodley et al., 1985; Ryynanen et al., 1992) , but it was thought that in human beings in vivo most of the type VII collagen at the BMZ of the skin came from keratinocytes (Regauer et al., 1990) . Goto and co-workers (2006) bring us good news, however, because dermal fibroblasts are much easier to work with and propagate than human keratinocytes. The conditions for culturing human dermal fibroblasts are far less fastidious than those for culturing human keratinocytes, so technical considerations are lessened. Fibroblasts are more robust cells than keratinocytes and are much less susceptible to growth arrest and differentiation than epidermal sheets, which are fragile and must be used immediately (Hengge and Bardenheuer, 2004) . Furthermore, fibroblasts can be passaged 20-30 times in vitro, are easy to grow in larger numbers, and can be readily cloned: a single genetically modified fibroblast can be expanded to greater than 10 20 cells (Krueger, 2000) .
In addition to the above considerations favoring gene-corrected dermal fibroblasts over keratinocytes as targets for gene therapy in DEB, it has been shown that gene-corrected recessive DEB fibroblasts and normal human dermal fibroblasts can be injected intradermally into a rodent or into a 1 DEB skin equivalent transplanted onto a rodent, after which the cells export type VII collagen at the injection site. Once the exogenous exported collagen is at the site, it attaches to the host's BMZ and then forms anchoring fibril structures that correct the DEB phenotype in DEB skin equivalents (Oritz-Urda et al., 2003; . How this process occurs is not clear. We and others have shown that human type VII collagen has specific domains with affinity for other BMZ macromolecules including laminin-5, fibronectin, and type IV collagen (Champioaud et al., 1996; Chen et al., 1997; Chen et al., 1999) . It is likely that the exported type VII collagen free in the extracellular spaces at the injection sites attaches to BMZ components and selectively adheres to the BMZ rather than remaining diffuse in the host's dermis.
Although it is clear that Goto and co-workers (2006) have succeeded in delivering the human gene for fulllength type VII collagen into DEB fibroblasts and keratinocytes using a retroviral approach, there are some arguments that favor using lentiviral vectors over using retroviral vectors. First, lentiviral vectors can infect both dividing and non-dividing cells, whereas retroviruses can infect only dividing cells (Naldini, 1998; Amado and Chen, 1999) . One goal is to deliver the transgene to stem cells, which are also known to be slowly dividing cells; therefore, it would appear that lentiviruses would have an advantage over retroviruses. Consistent with this notion, a recent study compared the efficiency of gene transfer into human keratinocytes of adenoviral vectors, adenovirus-associated virus, retroviral vectors, and lentiviral vectors, the most commonly used viral vectors (Gagnoux-Palacios et al., 2005) . Gagnoux-Palacios and coworkers concluded that lentiviral vectors were the most suitable for ex vivo gene therapy, because of their ability to transduce clonogenic primary keratinocytes (Gagnoux-Palacios et al., 2005) . Secondly, lentiviral vectors provide high transduction efficiency and sustained gene expression in vivo. In the study by Goto et al. (2006) , retrovirus produced a maximum transduction O nce delivered to the extracellular space near the BMZ, the collagen and its interaction with the host will fi gure everything else out efficiency of about 30% without the help of retronectin, whereas lentivirus can produce transduction efficiency of over 90% in human skin cells (Chen et al., 2003) . In a study comparing the efficiency of delivering human genes into skin cells by various methods, the lentivirus-mediated gene delivery approach was found to be the most efficient (Chen et al., 2003) . Nevertheless, maximal efficiency of delivering a collagen gene may not be necessary in the treatment of DEB. This is because collagens resist many proteases. Although the exact turnover time of type VII collagen in the skin is unknown, it is thought to be quite long, similar to that of other collagens (Burgeson, 1993) . In addition, it has been shown that heterozygous patients with a COL7A1 null mutation may have a 50% reduction in the anchoring fibrils in their skin, yet there is no evidence of an epidermolysis bullosa-like disease (Uitto and Christiano, 1994) . This observation suggests that only 50% of the normal number of anchoring fibrils provides significant dermal-epidermal adherence. However, the absolute minimal number of anchoring fibrils needed for "normal" dermal-epidermal adherence is not known. Finally, other advantages of lentiviral vectors should be mentioned. Lentiviral vectors can house very large human genes with little compromise of titers because of an ample cloning size of over 9 kb (Chen et al.) . Further, lentiviral vectors do not appear to induce a significant host immune response, unlike adenoviral vectors.
The Goto et al. study (2006) also complements other recent studies on strategies for DEB therapy in that it shows again the plasticity of the biology. Once this large, hockey stickshaped collagen is delivered to the extracellular space near the BMZ via intradermal injection, the collagen and its interaction with the host will figure everything else out, including how to get the exogenous collagen incorporated into the BMZ of the host, even across species. It has been shown that in addition to injecting fibroblasts into DEB models, one can also directly inject lentivirus harboring the human gene for type VII collagen intradermally into skin (Woodley et al., 2004b) .
These viruses then infect resident dermal cells in the area, including fibroblasts and endothelial cells, which then export the collagen into the extracellular space. Once again, type VII collagen in the extracellular space will home to the BMZ, incorporate there, and form anchoring fibril structures (Woodley et al., 2004b) . Perhaps even more interesting is the study showing that recombinant human type VII collagen directly injected intradermally into an animal or into a DEB skin equivalent grafted onto an animal will do the same thing -that is, home to the BMZ, incorporate there, make anchoring fibril structures, and even correct the DEB phenotype (Woodley et al., 2004a) . This strategy has the advantage of simplicity, directness, and technical ease. Dermatologists are very well versed at injecting bovine or recombinant type I collagen into human skin to improve fine rhytides. Therefore, it is theoretically feasible to inject recombinant type VII collagen into the high dermis of patients with DEB to restore type VII collagen and anchoring fibrils in their skin to reverse their skin fragility and blistering. Again, because we do not know the turnover time of type VII collagen, we do not know how long type VII collagen and anchoring fibrils delivered by this method would last. How often would these injections have to be repeated to keep the anchoring fibrils at sufficient functional numbers to maintain the epidermolysis bullosa phenotype reversal? Delivering gene-corrected cells such as fibroblasts via cell therapy or lentiviral vectors expressing type VII collagen may have the advantage of producing continuous type VII collagen α chains to the skin.
The other problem with all of these methods that require the intradermal injection of fibroblasts, vectors harboring the gene for type VII collagen within a viral system, or the recombinant protein itself is that many DEB patients have multiple wounds spanning large areas of trauma-prone sites such as the sacrum, hips, feet, lower back, and hands. These large areas would all need to be injected, probably repeatedly, although the injection time intervals are unknown. It would be advantageous to inject cells intravenously into the DEB patient, where they would home to the wound sites and deliver the transgene product. In this way, all of the patient's wound areas could be replenished with type VII collagen and anchoring fibrils at the same time. We have been experimenting with this model in the University of Southern California Laboratory for Investigative Dermatology.
In conclusion, the paper by Goto and colleagues (2006) supports the notion that fibroblasts are excellent targets for gene therapy for patients with DEB. They have many advantages over keratinocytes. Among these advantages are their technical ease of use and the ability of exogenously delivered fibroblasts to reside where delivered and continuously deliver type VII collagen to the host's BMZ, where it incorporates and forms anchoring fibril structures. These findings and a new appreciation for the plasticity of human skin biology should give hope to DEB patients and their families for improved therapy in the near future.
